IPSCCentury Therapeutics, Inc.

Nasdaq centurytx.com


$ 3.11 $ -0.06 (-1.9 %)    

Wednesday, 15-May-2024 15:59:00 EDT
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 3.09
$ 3.11
$ 3.09 x 100
$ 0.00 x 0
$ 3.08 - $ 3.19
$ 1.28 - $ 5.51
69,860
na
256M
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-century-therapeutics-lowers-price-target-to-11

HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price...

 century-therapeutics-q1-2024-gaap-eps-045-beats-052-estimate-sales-855000k-miss-1262m-estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of ...

 piper-sandler-reiterates-overweight-on-century-therapeutics-lowers-price-target-to-9

Piper Sandler analyst Edward Tenthoff reiterates Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price t...

 small-cap-firm-century-therapeutics-expands-into-autoimmune-diseases-analyst-says-clade-therapeutics-acquisition-intriguing

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including syste...

 century-therapeutics-strengthens-its-autoimmune-disease-portfolio-with-pipeline-expansion-supported-by-60m-private-placement-and-acquisition-of-clade-therapeutics

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond ...

 century-therapeutics-presents-new-preclinical-data-highlighting-ipsc-derived-cell-therapy-platform-technology-at-the-2024-aacr-annual-meeting

Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...

 canaccord-genuity-maintains-buy-on-century-therapeutics-raises-price-target-to-24

Canaccord Genuity analyst Bill Maughan maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and raises the price target f...

 hc-wainwright--co-reiterates-buy-on-century-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $13 p...

 century-therapeutics-fy-eps-230-misses-209-estimate-sales-223m-miss-382m-estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate o...

 century-therapeutics-to-present-preclinical-data-from-its-ipsc-derived-cell-therapy-platform-at-the-2024-american-association-for-cancer-research-annual-meeting

The upcoming abstracts highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene edit...

 russell-2000-rallies-to-16-month-highs-best-performing-small-cap-stocks-popping-over-80-in-december

Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 8...

 hc-wainwright--co-reiterates-buy-on-century-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $13 p...

 century-therapeutics-q3-eps-055-misses-051-estimate-sales-14800k-miss-116m-estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION